Table 4 Incidence and hazard ratios (HR) for cardiovascular diseases (CVD) and total mortality depending on the MCM6-rs3754686 proxy for milk intake after 4.8 years of median follow-up in the PREDIMED trial.

	CVD incidence (men + women): n = 7,185										Model 3	Model 4
	Cases	Non-cases	person-y	Incidence rate*	Model 1			Model 2			Model 3	Model 4
	Cases	Non-cases	person-y	Incidence rate*	HR	95% CI	P-value	HR	95% CI	P-value	P-value	P-value
MCM6 genotypes**
TT	74	1908	8612	8.6	1.00	(reference)		1.00	(reference)
CT	136	3410	15361	8.9	1.04	(0.79–1.39)	0.768	1.02	(0.77–1.36)	0.890	0.941	0.945
CC	57	1600	7016	8.1	0.94	(0.66–1.33)	0.733	0.95	(0.69–1.35)	0.764	0.981	0.815
TT (ref.)***					1.00	(reference)		1.00	(reference)
(CC + TC) vs TT					1.01	(0.77–1.33)	0.932	1.00	(0.76–1.31)	0.989	0.928	0.969
Per variant allele (T)****					1.03	(0.87–1.22)	0.767	1.02	(0.86–1.22)	0.785	0.792	0.829
P^§-interaction sex*MCM6 polymorphism: 0.005
	Total mortality (men + women): n = 7,185
					Model 1			Model 2			Model 3	Model 4
MCM6 genotypes**
TT	104	1878	8622	12.1	1.00	(reference)		1.00	(reference)
CT	139	3407	15375	9.0	0.73	(0.58–0.97)	0.029	0.75	(0.58–0.97)	0.028	0.028	0.030
CC	79	1579	7027	11.2	0.89	(0.86–1.19)	0.424	0.89	(0.66–1.21)	0.464	0.455	0.549
TT (ref.)***					1.00	(reference)		1.00	(reference)
(CC + CT) vs TT					0.80	(0.63–1.01)	0.057	0.79	(0.62–1.01)	0.058	0.057	0.068
Per variant allele (T)****					1.08	(0.92–1.26)	0.338	1.07	(0.92–1.26)	0.378	0.371	0.446
P^§§-interaction sex*MCM6 polymorphism: 0.032

*Crude incidence rates were expressed per 1000 person-years of follow-up.
**Codominant model. ***Recessive model.****Additive model.
We used multivariable Cox regression models with length of follow-up as the primary time variable. Separate models were fitted for CVD and total mortality to estimate the corresponding HRs depending on the model.
Model 1: Adjusted for sex, age, field center and dietary intervention group.
Model 2: Model 1 adjusted for variables in model 1 plus BMI, diabetes, drinking, smoking, physical activity, medication (hypertension, dyslipidemia and glucose) and total energy intake at baseline.
Model 3: Model 2 adjusted for variables in model 2 plus total milk intake. Model 4: Model 3 additionally adjusted for total fat and carbohydrates at baseline.
^§P-value for interaction sex*MCM6 polymorphism in determining CVD incidence, obtained in Model 2. Further adjustments did not change the statistical significance.
^§§P-value for interaction sex*MCM6 polymorphism in determining mortality, obtained in Model 2. Further adjustments did not change the statistical significance.

Search